低分子肝素与小剂量尿激酶治疗进展性脑卒中疗效比较

目的：探讨小剂量尿激酶和低分子肝素对急性进展性缺血性脑卒中的治疗作用。方法：将60例急性进展性脑卒中患者随机分成低分子肝素组30例，予低分子肝素0．4ml，2次／d，皮下注射；尿激酶组30例，予尿激酶20～30万单位加生理盐水100ml静滴，连用7d；于治疗前、治疗7d比较两组神经功能缺损评分。结果：低分子肝素组治疗总有效率90．0％，尿激酶组83．3％，二者比较差异无统计学意义（P〉0．05），但尿激酶组出血副作用较大。结论：低分子肝素治疗急性进展性脑卒中较小剂量尿激酶的疗效可靠，相对安全。

Comparison of Therpeutic Effect of Low-molecular Weight-heparin and Low-dose Urokinase in Treatment of Acute Progressive Ischemic Stroke

Objective：To investigate the effect of low - dose urokinase and low - molecular - weight heparin on acute progressive ischemic stroke. Methods： 60 patients with acute progressive ischemic stroke were randomly divided into two groups. 30 patients received 0.4 ml of low - molecular - weight heparin by hypodermic injection two times a day;30 patients received low- dose urokinase 200 000-300 000 u addition to 100 ml normal saline by intravenous drip. Two groups were all used for 7 days. Compared before treatment with 7 days treatment lat- er. Neurological deficits score were used . Results： The total effective rate of low - molecular weight heparin was 90.0 %, and low dose urokinase was 83.3 %, there was no difference between two groups（P〉 0.05）. But uroki- nase had the heavy hemrrohage side effect. Conclusion： The therapeutic effect of low - molecular - weight hep-arin on acute progressive ischemic stroke was more progressive and safe than low- dose urokinase.